CCSG Developmental Funds are important to allow Roswell Park Comprehensive Cancer Center leadership opportunities to pursue new initiatives that align with the strategic plan. The funds provide support for strategic priorities that further the cancer center mission. CCSG Developmental Funds are usually leveraged alongside institutional and philanthropic funds to support key faculty recruitment, shared resource development and innovative pilot projects. During the current project period, CCSG developmental funds supported 9 new faculty investigators; significant investment in shared resources to develop new techniques and to enhance new utilization of shared resource services; and 24 pilot projects. These efforts have catalyzed collaborative efforts within and across CCSG Programs that have yielded an impressive overall return on investment, measured as publications and grants awarded as a result of the pilot research. The CCSG/ Roswell Park Alliance Foundation Scientific Advisory Committee process administers and oversees allocation of cancer center pilot project funding. Meritorious, high impact, high risk projects are considered through this funding mechanism. This process has worked well to ensure internal, peer-review of the applications. Candace Johnson, CCSG PI ultimately manages the allocation process and ensures requests are in line with the Strategic Plan and cancer center priorities. CCSG Developmental Funds add value by providing a flexible, dynamic source of funding that further the overall mission and priorities of the center. Developmental Funds provide the opportunity to fund innovative pilot projects, support new shared resources or enhance existing shared resources with new technologies, and recruit key faculty in alignment with the strategic plan. During the next grant period, funds will support recruitment, shared resources: ? Recruitments: The Center will recruit 2 key investigators per year. Developmental funds of $300,000 a year will be used to support new investigators in each of the CCSG programs over project period. ? Shared Resources: The Center will use $100,000 a year to help develop new Shared Resources such as Community Engagement Shared Resource, invest funds in new technologies to enhance existing shared resources. ? Pilot Grants: Grants will be awarded to individual investigators through the Scientific Advisory Committee (SAC) process, to each research program, and for Team Science. Strategic emphasis will be placed on funding proposals that are collaborative and interdisciplinary in order to encourage large multi-investigator initiatives and grants. Developmental funds of $200,000 a year will be used to support pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-43
Application #
9923590
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
43
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Mohammadpour, Hemn; O'Neil, Rachel; Qiu, Jingxin et al. (2018) Blockade of Host ?2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. J Immunol 200:2479-2488

Showing the most recent 10 out of 1555 publications